Immunomodulation exerted by galectins: a land of opportunity in rare cancers.
cancer
cell signaling
galectins
immunomodulation
rare cancer
therapeutics
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2023
2023
Historique:
received:
24
09
2023
accepted:
25
10
2023
medline:
1
12
2023
pubmed:
29
11
2023
entrez:
29
11
2023
Statut:
epublish
Résumé
Rare cancers represent only 5% of newly diagnosed malignancies. However, in some cases, they account for up to 50% of the deaths attributed to cancer in their corresponding organ. Part of the reason is that treatment options are generally quite limited, non-specific, and very often, only palliative. Needless to say, research for tailored treatments is warranted. Molecules that exert immunomodulation of the tumor microenvironment are attractive drug targets. One such group is galectins. Thus, in this review we summarize the current knowledge about galectin-mediated immunomodulation in rare cancers, highlighting the research opportunities in each case.
Identifiants
pubmed: 38022609
doi: 10.3389/fimmu.2023.1301025
pmc: PMC10663293
doi:
Substances chimiques
Galectins
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1301025Informations de copyright
Copyright © 2023 Díaz-Alvarez, López-Cortés and Pérez-Figueroa.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Cancer Cell. 2019 Jun 10;35(6):868-884.e6
pubmed: 31185211
Mod Pathol. 2005 Jan;18(1):48-57
pubmed: 15272279
Oncotarget. 2016 Dec 13;7(50):83611-83626
pubmed: 27835885
Cancer Immunol Immunother. 2018 Feb;67(2):209-224
pubmed: 29051990
Front Endocrinol (Lausanne). 2021 Aug 19;12:708949
pubmed: 34489865
Adv Exp Med Biol. 2012;946:21-36
pubmed: 21948360
Br J Cancer. 2009 May 5;100(9):1406-14
pubmed: 19401700
Br J Cancer. 2018 Jan;118(1):52-61
pubmed: 29136404
Histopathology. 2002 Sep;41(3):236-43
pubmed: 12207785
Clin Orthop Relat Res. 2002 Apr;(397):70-5
pubmed: 11953597
Histopathology. 2005 Oct;47(4):391-401
pubmed: 16178894
Curr Oncol Rep. 2007 Mar;9(2):152-8
pubmed: 17288883
Croat Med J. 2021 Apr 30;62(2):110-119
pubmed: 33938650
Oncotarget. 2017 Jun 27;8(37):61935-61943
pubmed: 28977916
J Pers Med. 2023 Feb 27;13(3):
pubmed: 36983607
Br J Cancer. 2020 Nov;123(10):1521-1534
pubmed: 32801345
Best Pract Res Clin Gastroenterol. 2022 Jun-Aug;58-59:101800
pubmed: 35988963
Oncotarget. 2017 Sep 21;8(60):101475-101488
pubmed: 29254179
J Immunother Cancer. 2021 Apr;9(4):
pubmed: 33837055
Oncol Lett. 2013 Jul;6(1):86-90
pubmed: 23946782
Proc Natl Acad Sci U S A. 2002 Sep 17;99(19):12293-7
pubmed: 12218188
Arch Pathol Lab Med. 2004 Jan;128(1):54-8
pubmed: 14692811
Sci Adv. 2022 Jul 8;8(27):eabl5165
pubmed: 35857445
Endocrinol Metab Clin North Am. 2019 Mar;48(1):285-301
pubmed: 30717909
CA Cancer J Clin. 2022 Jan;72(1):7-33
pubmed: 35020204
Nat Commun. 2021 Feb 5;12(1):832
pubmed: 33547304
Cancer Causes Control. 2001 Jan;12(1):1-11
pubmed: 11227920
Oncol Rep. 2016 Feb;35(2):851-60
pubmed: 26717877
Science. 2007 Nov 16;318(5853):1141-3
pubmed: 18006747
Histopathology. 2004 Nov;45(5):493-500
pubmed: 15500653
J Lab Physicians. 2018 Apr-Jun;10(2):200-207
pubmed: 29692588
Am J Transl Res. 2016 Apr 15;8(4):1641-58
pubmed: 27186290
Sci Adv. 2022 Feb 18;8(7):eabl3674
pubmed: 35171675
Arch Pathol Lab Med. 2002 Jun;126(6):710-3
pubmed: 12033961
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
J Cell Biochem. 2017 Nov;118(11):3911-3919
pubmed: 28390192
Oncol Lett. 2017 Jul;14(1):819-829
pubmed: 28693238
J Pathol. 2009 May;218(1):66-75
pubmed: 19199318
Oncol Rep. 2015 Oct;34(4):1761-70
pubmed: 26260906
Nat Rev Drug Discov. 2023 Apr;22(4):295-316
pubmed: 36759557
Med Sci Monit. 2015 Mar 13;21:755-60
pubmed: 25765552
J Exp Clin Cancer Res. 2022 Jan 7;41(1):14
pubmed: 34996504
Oncol Rep. 2015 Oct;34(4):2099-105
pubmed: 26239720
J Clin Diagn Res. 2015 Nov;9(11):EC07-11
pubmed: 26673516
Clin Endocrinol (Oxf). 2002 Dec;57(6):813-9
pubmed: 12460332
Ann Oncol. 2005;16 Suppl 2:ii93-6
pubmed: 15958484
Oncotarget. 2013 Sep;4(9):1461-71
pubmed: 23985992
Mol Cancer Ther. 2010 Aug;9(8):2208-19
pubmed: 20682656
Int J Oncol. 2017 Sep;51(3):760-770
pubmed: 28677745
Cancer Sci. 2009 Nov;100(11):2077-84
pubmed: 19723119
J Clin Pathol. 2003 Feb;56(2):142-3
pubmed: 12560396
Korean J Pathol. 2014 Jun;48(3):234-40
pubmed: 25013423
Int J Clin Exp Pathol. 2015 Jul 01;8(7):8268-75
pubmed: 26339396
J Nucl Med. 2019 Jun;60(6):770-776
pubmed: 30361380
Life Sci. 2023 Apr 1;318:121480
pubmed: 36775116
Oncol Lett. 2016 Mar;11(3):1829-1834
pubmed: 26998085
Front Immunol. 2022 Jan 25;12:797407
pubmed: 35145510
J Neurosurg. 1997 Feb;86(2):182-9
pubmed: 9010416
Biomolecules. 2023 May 29;13(6):
pubmed: 37371482
Cell Death Discov. 2015 Nov 02;1:15047
pubmed: 27551476
Cancer Immunol Immunother. 2019 Jul;68(7):1157-1169
pubmed: 31197461
Neoplasia. 2013 Jul;15(7):773-82
pubmed: 23814489
Am J Surg Pathol. 2006 Jul;30(7):811-8
pubmed: 16819322
Sci Rep. 2021 Feb 12;11(1):3718
pubmed: 33580170
Best Pract Res Clin Gastroenterol. 2021 Mar-Apr;50-51:101728
pubmed: 33975682
Histopathology. 2002 Jan;40(1):80-7
pubmed: 11903601
Front Endocrinol (Lausanne). 2022 Jul 08;13:860671
pubmed: 35872981
Cancers (Basel). 2021 Sep 26;13(19):
pubmed: 34638305
J Pathol. 1997 Jan;181(1):80-6
pubmed: 9072007
Chem Biol Interact. 2019 Aug 25;309:108724
pubmed: 31228468
Austin Virol Retro Virol. 2014;1(2):
pubmed: 26539564
Biochim Biophys Acta Mol Basis Dis. 2023 Jan 1;1869(1):166591
pubmed: 36328145
Am J Hum Genet. 2016 May 5;98(5):830-842
pubmed: 27087319
Cancer. 2011 Feb 15;117(4):826-31
pubmed: 20925044
Nat Med. 2002 Aug;8(8):793-800
pubmed: 12091876
Int J Cancer. 1995 Jun 22;64(3):171-5
pubmed: 7622305
Oncotarget. 2016 Mar 22;7(12):15150-60
pubmed: 26934444
Bull Exp Biol Med. 2019 Apr;166(6):774-778
pubmed: 31028580
Cancer Biol Med. 2017 Aug;14(3):319-326
pubmed: 28884048
Int Immunopharmacol. 2017 Mar;44:153-159
pubmed: 28103502
Cancers (Basel). 2022 Dec 28;15(1):
pubmed: 36612173
Cancer Res. 2006 Mar 15;66(6):3114-9
pubmed: 16540661
Appl Immunohistochem Mol Morphol. 2013 May;21(3):237-41
pubmed: 23235344
Oncogene. 2022 Dec;41(50):5319-5330
pubmed: 36335283
Gastroenterology. 2013 Dec;145(6):1215-29
pubmed: 24140396
Clin Oncol (R Coll Radiol). 2010 Aug;22(6):486-97
pubmed: 20418080
Cancer Res. 2007 Sep 1;67(17):8344-50
pubmed: 17804750
Int J Surg. 2017 May;41 Suppl 1:S2-S6
pubmed: 28506408
Sci Rep. 2021 Jun 10;11(1):12264
pubmed: 34112882
Asian Pac J Cancer Prev. 2001;2(2):117-121
pubmed: 12718642
Int J Mol Sci. 2012;13(2):1886-1918
pubmed: 22408430
Lancet Oncol. 2015 Feb;16(2):e60-70
pubmed: 25638682
Mod Pathol. 2009 Aug;22(8):996-1005
pubmed: 19407855
Neuroendocrinology. 2020;110(9-10):836-847
pubmed: 32541136
Wien Klin Wochenschr. 2015 May;127(9-10):337-44
pubmed: 25471003
Head Neck Pathol. 2017 Jun;11(2):162-167
pubmed: 27550513
Immunol Invest. 2017 Feb;46(2):134-148
pubmed: 27911104
J Pathol. 2012 Sep;228(1):56-66
pubmed: 22513979
Cancer Treat Rev. 2016 Nov;50:89-98
pubmed: 27664392
Trop Med Int Health. 2004 May;9(5):588-94
pubmed: 15117303
Biomolecules. 2022 Sep 13;12(9):
pubmed: 36139125
Anticancer Res. 1998 Jul-Aug;18(4A):2637-41
pubmed: 9703921
Arch Otolaryngol Head Neck Surg. 2007 May;133(5):503-10
pubmed: 17515507
Histopathology. 2000 Dec;37(6):530-5
pubmed: 11122435
Am J Clin Pathol. 2006 Mar;125(3):399-406
pubmed: 16613808
World Neurosurg. 2017 Nov;107:75-81
pubmed: 28647652
Ann Oncol. 2009 Nov;20(11):1886-94
pubmed: 19570961
Sci Rep. 2019 Feb 18;9(1):2186
pubmed: 30778105
Cells. 2021 May 05;10(5):
pubmed: 34063063
Br J Cancer. 2012 May 8;106(10):1668-74
pubmed: 22569001